14 results about "Ldl cholesterol" patented technology

The invention provides a preparation method of an apple water kefir beverage and application of the apple water kefir beverage in lowering cholesterol. The method comprises the following steps: preparing apple juice, activating water kefir grains, inoculating the activated water kefir grains into the apple juice, and fermenting to prepare the apple water kefir beverage. The volatile component change in the fermentation process is analyzed through GC-MS and GC-IMS systems, it is proved that the unique bouquet characteristic and flavor coordination of the apple water kefir beverage are improved through water kefir grain fermentation, and meanwhile the organic acid composition is optimized. A mouse model verifies that the apple water kefir beverage has the effect of reducing cholesterol, can reduce liver lipid droplets, total cholesterol, low-density lipoprotein and triglyceride levels, and also can regulate intestinal microbial communities (increase firmicobacteria, bacteroides and faecalis bacteria). The apple water kefir beverage disclosed by the invention has wide market potential and provides a scientific basis for the development of functional beverages.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

Conventionally, it has been necessary to collect blood of a subject and perform biochemical analysis to measure LDL cholesterol and HDL cholesterol. However, in this method, a needle or the like needs to be invasively inserted into the skin of the subject, which causes a psychological or physical burden on the subject. According to the present invention, it is possible to non-invasively estimate cholesterol based on attribute information and / or non-invasive biological information of a predetermined user by generating a cholesterol estimation model by machine learning based on attribute information, non-invasive biological information, and blood examination data acquired from a plurality of subjects in advance.

Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and / or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower IL2, INFγ, and IL17a. The use of such peptides to increase glucose transport protein (GLUT4). Methods and materials for detecting T-cells that express CD40 (Th40 cells).

The problem to be solved by the present invention is to provide a targeted anti-inflammatory therapy that reduces the self-perpetuating metabolic inflammation due to local LDL cholesterol in atherosclerotic plaques without significant systemic immunosuppression.SOLUTION: The present invention provides a polypeptide dimer comprising two gp130 - Fc fusion peptides for use in the treatment of ASCVD in human patients, preferably high risk ASCVD in human patients, more preferably very high risk ASCVD in human patients.SELECTED DRAWING: None

Provided is a novel preparation having an excellent lipolysis-promoting effect, an excellent visceral fat and body fat reducing effect, an excellent body weight reducing effect, and an excellent BMI improving effect. Another purpose of the present invention is to provide a novel preparation having an excellent insulin resistance improving effect, an excellent cholesterol value reducing effect, and the like. The present invention is an internal composition containing hirsutin B, which is used for at least one of lipolysis, fat burning, fat consumption assistance, BMI improvement, BMI reduction assistance, abdominal fat reduction, visceral fat reduction, body fat reduction, waist reduction, insulin resistance improvement, and LDL cholesterol value reduction. The internal composition of the present invention is preferably used for adults having a BMI of 23 kg / m < 2 > or more and less than 30 kg / m < 2 > and for adults having a visceral fat area of 100 cm < 2 > or more.

Provided is a method of assisting the detection of nonalcoholic steatohepatitis (NASH), which is far less invasive than liver biopsy and is based on simple operations that do not require skilled technical personnel.The present invention is a method of assisting the detection of NASH, which includes:a) measuring the amount of LDL-TG contained in a test blood sample isolated from a living body;b) measuring the amount of at least one component selected from the group consisting of LDL-C, LDL subfraction-C, IIDL-C, HDL subfraction-C, ApoB, ApoE, total cholesterol, ALT, and AST contained in the test blood sample; andc) determining the possibility of developing and / or having NASH by using the amount of LDL-TG in combination with the amount of the at least one component.

A reagent composition containing an anionic surfactant, in which the reagent composition is used as a first reagent composition in a method for quantifying a sdLDL-C in a sample, the method including acting the first reagent composition on a sample, and subsequently acting a second reagent composition for quantifying the sdLDL-C to quantify cholesterol in a remaining lipoprotein, the reagent composition has cholesterol esterase activity and cholesterol oxidase activity, and also has at least one activity selected from the group made of peroxidase activity and catalase activity, and a contact angle between the reagent composition and a polyethylene terephthalate (PET) base material is equal to or more than 65° and equal to or less than 77°.

Provided herein are pharmaceutical compositions comprising obicetrapib, or a pharmaceutically acceptable salt, solvate or co-crystal thereof, including, for example, obicetrapib calcium, obicetrapib calcium which, as used herein, is obicetrapib hemicalcium, and which may, in many embodiments, be amorphous obicetrapib hemicalcium; and optionally one or more additional pharmaceutically acceptable excipients. Also provided are pharmaceutical dosage forms including the same processes for making such pharmaceutical compositions, and methods for using such pharmaceutical compositions in the treatment of subjects including in treatments requiring reduction in LDL cholesterol and / or an increase in HDL cholesterol and other ailments.

The invention discloses a shark source single-domain antibody targeting LRP6 and application of the shark source single-domain antibody. The single-domain antibody has an amino acid sequence as shown in SEQ ID NO: 1, shows nanomole-level high affinity to LRP6 protein, has an affinity constant KD value of 1.8 * 10 <-9 > M, shows excellent physical and chemical stability, has a thermal denaturation temperature as high as 75.6 DEG C, and can still retain 92% or more of binding activity after being incubated for 2 hours under a strong acidic condition. Meanwhile, the antibody has high specificity, and the cross reaction rate of the antibody with homologous protein LRP5 and homologous protein LDLR is lower than 4%. The invention also provides a composition for reducing hypertension, hyperglycemia and hyperlipidemia, which contains the single-domain antibody and a specific natural plant extract composite component. Experiments show that the composition can synergistically act on a plurality of pathological links of the metabolic syndrome, the symptoms of hyperglycemia, hyperlipidemia and hypertension are remarkably improved in an animal model, the effect is better than that of a single component and a traditional control drug, and a brand new multi-target treatment scheme is provided for prevention and treatment of the metabolic syndrome.

Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4′ and 2′ positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.

A novel preventive and / or therapeutic agent useful in the prevention and / or treatment of a disease on which a therapeutic effect can be expected by a reduction in blood LDL-C. The present invention relates to a medicine for preventing and / or treating a disease on which a therapeutic effect can be expected by a reduction in blood LDL-C, the medicine including a therapeutically effective dose of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid or a salt thereof, or a solvate thereof.

To provide a composition that can promote the production of IL-10 in intestinal epithelial cells. [Solution] A composition containing dead lactic acid bacteria belonging to the genus Lactiplantibacillus, which has an effect of promoting IL-10 production in intestinal epithelial cells, promotes the production of IL-10, an anti-inflammatory immune-related cytokine, in intestinal epithelial cells, thereby increasing or suppressing the decrease in blood IL-10 concentration, preventing or improving liver function decline, preventing or improving cholestasis, reducing total blood cholesterol or LDL cholesterol, promoting the polarization of macrophages from M1 to M2, or suppressing the decline in skin barrier function.